This, consequently, could induce deleterious CIN in CIN-resistant cancers, highlighting the potential of pharmacological MASTL inhibitors as therapeutic agents that induce fetal CIN in cancer. The gene discussed is MASTL; the disease is cervical squamous intraepithelial neoplasia.